Market capitalization | CHF145.58m |
Enterprise Value | CHF1.12b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 15.87 |
P/S ratio (TTM) P/S ratio | 2.06 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -61.76% |
Revenue (TTM) Revenue | CHF70.62m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Idorsia forecast:
3 Analysts have issued a Idorsia forecast:
Sep '24 |
+/-
%
|
||
Revenue | 71 71 |
62%
62%
|
|
Gross Profit | 39 39 |
75%
75%
|
|
EBITDA | -369 -369 |
39%
39%
|
EBIT (Operating Income) EBIT | -385 -385 |
38%
38%
|
Net Profit | -283 -283 |
24%
24%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus. The was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.
Head office | Switzerland |
CEO | André Muller |
Founded | 2017 |
Website | www.idorsia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.